Projects

CARDINNATE: Variation in innate immune activation and cardiovascular disease risk as drivers of immune pathology in COVID19 outcome in South Asians in UK and India

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2021 - Ongoing

Project Lead

Dr. Mary Dias

Authors

Dr. Mary Dias

Project Status

ongoing

Project Type

DBT-EU